Navigation Links
Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory

Accomplished regulatory executive enhances Nfocus device development team.

PALO ALTO, Calif., April 30 /PRNewswire/ -- Endovascular device start-up Nfocus Neuromedical Inc. announced today the appointment of accomplished regulatory executive Robert O'Holla to its leadership team in the role of Vice President of Regulatory Affairs.

"Bob O'Holla brings an unmatched wealth of regulatory and compliance experience to Nfocus, having served 18 of his last 30 years in the industry in the role of Worldwide Vice President of Regulatory Affairs, Medical Devices, for Johnson & Johnson," said President and CEO Martin Dieck. "His disciplined and strategic approach to the product development and approval processes set him apart as a worldwide expert. We are thrilled to welcome him to Nfocus Neuromedical."

O'Holla has an extensive background in the fields of R&D, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its next-generation endovascular devices. He chaired the Technology and Regulatory Advisory Committee at AdvaMed, a premier medical technology industry group for 13 years, and was a key figure in the construction of the Medical Device User Fee and Modernization Act of 2002, which amended and refined food and drug law related to medical devices.

"I welcome the challenges and rewards of serving in my new role with Nfocus," noted O'Holla, "as we strive to bring responsible and innovative products and technological solutions to the emerging field of endovascular neurosurgery."

About Nfocus Neuromedical, Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices). Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.

Nfocus was incubated at In-Cube Labs and is backed by Oxford Bioscience Partners, Technology Partners and DFJ-ePlanet Ventures. To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the new Nfocus website at:

For more information about aneurysms and hemorrhagic stroke see: and

SOURCE Nfocus Neuromedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
2. Vasogen Appoints Dr. Eldon Smith Chairman
3. DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
4. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
5. Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
6. Ventus Medical Appoints John McCutcheon as President and CEO
7. Sinobiopharma, Inc. Appoints New Director of Marketing
8. Yongye Biotechnology Appoints New Chief Financial Officer
9. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today announced ... Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):